​

DiaMedica Therapeutics (DMAC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DMAC Stock Forecast

DiaMedica Therapeutics stock forecast is as follows: an average price target of $8.50 (represents a 32.61% upside from DMAC’s last price of $6.41) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

DMAC Price Target

The average price target for DiaMedica Therapeutics (DMAC) is $8.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $7.00. This represents a potential 32.61% upside from DMAC's last price of $6.41.

DMAC Analyst Ratings

Buy

According to 4 Wall Street analysts, DiaMedica Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DMAC stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

DiaMedica Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2024Bill ChappellTruist Financial$10.00$4.42126.46%56.01%
Oct 07, 2024Matthew CaufieldH.C. Wainwright$7.00$4.3660.55%9.20%
Mar 21, 2024Alex NowakCraig-Hallum$8.00$2.69197.40%24.80%

The latest DiaMedica Therapeutics stock forecast, released on Oct 07, 2024 by Bill Chappell from Truist Financial, set a price target of $10.00, which represents a 126.46% increase from the stock price at the time of the forecast ($4.42), and a 56.01% increase from DMAC last price ($6.41).

DiaMedica Therapeutics Price Target by Period

1M3M12M
# Anlaysts-23
Avg Price Target-$8.50$8.33
Last Closing Price$6.41$6.41$6.41
Upside/Downside-100.00%32.61%29.95%

In the current month, the average price target of DiaMedica Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DiaMedica Therapeutics's last price of $6.41. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2024H.C. WainwrightBuyInitialise
Jun 22, 2023OppenheimerOutperformUpgrade
Jun 22, 2023OppenheimerHoldUpgrade
Jul 07, 2022Lake StreetBuyBuyHold
Jul 07, 2022Craig-HallumBuyBuyHold

DiaMedica Therapeutics's last stock rating was published by H.C. Wainwright on Oct 07, 2024. The company Initialise its DMAC rating from "null" to "Buy".

DiaMedica Therapeutics Financial Forecast

DiaMedica Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast$13.50M$13.50M$13.50M$13.50M-------
High Forecast$13.50M$13.50M$13.50M$13.50M-------
Low Forecast$13.50M$13.50M$13.50M$13.50M-------
# Analysts1111-------
Surprise %-----------

DiaMedica Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DMAC's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

DiaMedica Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111-------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict DMAC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than DiaMedica Therapeutics's previous annual EBITDA (undefined) of $NaN.

DiaMedica Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111-------
Net Income-----------
Avg Forecast$-8.12M$-8.12M$-8.12M$-8.12M$-9.83M$-10.26M$-8.98M$-8.55M$-7.37M$-6.63M$-5.96M
High Forecast$-8.12M$-8.12M$-8.12M$-8.12M$-9.83M$-10.26M$-8.98M$-8.55M$-6.94M$-6.63M$-5.96M
Low Forecast$-8.12M$-8.12M$-8.12M$-8.12M$-9.83M$-10.26M$-8.98M$-8.55M$-7.81M$-6.63M$-5.96M
Surprise %-----------

DiaMedica Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DMAC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

DiaMedica Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111-------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

DiaMedica Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DMAC last annual SG&A of $NaN (undefined).

DiaMedica Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts1111-------
EPS-----------
Avg Forecast$-0.19$-0.19$-0.19$-0.19$-0.23$-0.24$-0.21$-0.20$-0.17$-0.15$-0.16
High Forecast$-0.19$-0.19$-0.19$-0.19$-0.23$-0.24$-0.21$-0.20$-0.16$-0.15$-0.16
Low Forecast$-0.19$-0.19$-0.19$-0.19$-0.23$-0.24$-0.21$-0.20$-0.18$-0.15$-0.16
Surprise %-----------

According to undefined Wall Street analysts, DiaMedica Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DMAC previous annual EPS of $NaN (undefined).

DiaMedica Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
MISTMilestone Pharmaceuticals$1.82$10.00449.45%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
SCPHscPharmaceuticals$3.25$13.00300.00%Buy
LYRALyra Therapeutics$0.18$0.50177.78%Hold
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
IKTInhibikase Therapeutics$3.97$6.5063.73%Buy
DMACDiaMedica Therapeutics$5.20$8.5063.46%Buy
IOVAIovance Biotherapeutics$7.81$12.4058.77%Buy
MCRBSeres Therapeutics$0.88$1.2542.05%Buy
HOOKHOOKIPA Pharma$2.13$3.0040.85%Buy
CNTACentessa Pharmaceuticals$17.60$23.2532.10%Buy

DMAC Forecast FAQ

Is DiaMedica Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, DiaMedica Therapeutics (DMAC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of DMAC's total ratings.

What is DMAC's price target?

DiaMedica Therapeutics (DMAC) average price target is $8.5 with a range of $7 to $10, implying a 32.61% from its last price of $6.41. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will DiaMedica Therapeutics stock go up soon?

According to Wall Street analysts' prediction for DMAC stock, the company can go up by 32.61% (from the last price of $6.41 to the average price target of $8.5), up by 56.01% based on the highest stock price target, and up by 9.20% based on the lowest stock price target.

Can DiaMedica Therapeutics stock reach $10?

DMAC's average twelve months analyst stock price target of $8.5 does not support the claim that DiaMedica Therapeutics can reach $10 in the near future.

What are DiaMedica Therapeutics's analysts' financial forecasts?

DiaMedica Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-37.621M (high $-37.621M, low $-37.621M), average SG&A $0 (high $0, low $0), and average EPS is $-0.88 (high $-0.88, low $-0.88). DMAC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $54M (high $54M, low $54M), average EBITDA is $0 (high $0, low $0), average net income is $-32.491M (high $-32.491M, low $-32.491M), average SG&A $0 (high $0, low $0), and average EPS is $-0.76 (high $-0.76, low $-0.76).